Press release from Companies
Publicerat: 2020-03-30 16:23:21
Due to the strain COVID-19 is causing on healthcare systems, WntResearch has put patient recruitment on hold in Spain and intends to do so at the recently activated Hungarian clinics as well. These measures are taken in accordance with the Spanish and Hungarian health authorities' directives. The decision has been made in consultation with the principal investigators of the clinical trials, as the current healthcare conditions in Spain and the uncertainty in Hungary is making it difficult to conduct a clinical trial such as NeoFox. The trials will resume as soon as the healthcare situation allows it.
The Spanish health situation is very dire and COVID-19 has impacted society at large as well as some of the clinics included in the NeoFox study. To continue recruitment under these circumstances would jeopardize the health of the patients as well as the integrity of the study. The patients currently receiving treatment in Spain are being offered to finish their treatment before the clinics stop recruiting new patients. In Hungary, healthcare is under tremendous pressure due to COVID-19 as well, and recruitment is on hold as a consequence. A pause will not lead to any administrative requirements when starting up again. As soon as the Company, in consultation with hospitals and principal investigators, makes the assessment that it is possible, the study will restart without delay. As long as the current COVID-19 outbreak requires the full commitment of healthcare systems, it is not possible to predict when the NeoFox study can be restarted. "We are all informed about the healthcare situation in the hospitals and the recommendations that have been issued to reduce the spread of COVID-19; visits should be limited to avoid the risk of additional coronavirus infections in the hospitals. The ethical, moral and logistic conditions required to conduct NeoFox are very difficult to achieve under these circumstances. Until recruitment can be restarted, the Company is addressing the impact from COVID-19 to the best of its ability in order to reduce the costs of the ongoing phase 2 study as well as internally. Recruitment will be able to commence swiftly and efficiently as soon as the healthcare situation allows it," says WntResearch's CEO, Peter Morsing. For more information, please contact: Peter Morsing, CEO, WntResearch AB Telephone: +46 727 200711 This information is information that WntResearch AB is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through the agency of the contact person set out above, on 30 March 2020. About WntResearch WntResearch is developing an entirely new kind of cancer drug, which inhibits the tumour cells' ability to spread through the body and metastasize. The majority of cancer deaths are due to metastases, and there are no therapies available that can prevent that. Foxy-5, the Company's most advanced drug candidate, is a peptide that mimics the body's own WNT5A protein. In preclinical trials, Foxy-5 has demonstrated ability to suppress the mobility and invasive power of cancer cells, and thus to inhibit metastasis. Phase 1 studies on patients with colon, prostate and breast cancer have demonstrated a good safety profile and favourable pharmacokinetics, and early data indicates biological activity. A Phase 2 multicenter study is underway on patients with colon cancer, in order to study the anti-metastasizing efficacy of Foxy-5. WntResearch's share is listed on Spotlight Stock Market. For more information, please visit: www.wntresearch.com
E-mail: pm@wntresearch.com
